[email protected]23 Nov, 2021News
Satish Mehta, MD & CEO, Emcure Pharma is currently having a moment under the sun. Emcure?s subsidiary, Gennova, is developing India?s first indigenously developed mRNA COVID-19 vaccine that is currently undergoing phase II and phase III trials. Mehta is confident about meeting the said target of 60 million doses by the end of 2021, despite the logistics challenges. The company is working towards backward integration of its operations to help de-risk the supply chain.
Uk88 Aitcom
Comet Estimating Llc
Sunwin Tài Xỉu, Game Bài
E2bet Immo
Good88am
Jin88
Rebihajihan
Red88 Brcom
E2bet Cool
Jin88t1 In Net